ClinicalTrials.gg
RecruitingNCT06007547PreProMISeUpdated Aug 7, 2025

Prophylactic Minimally Invasive Surfactant Evaluation

A Phase 4 interventional study of Poractant Alfa in Respiratory Distress Syndrome, Newborn and Premature Birth, sponsored by Endeavor Health. Recruiting at 1 site in United States. Open to participants aged Up to 15 Minutes, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Endeavor Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
Up to 15 Minutes
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Respiratory Distress Syndrome, Newborn · United States.

Planned enrollment
8th of 29
200 · median 93
Started
2024
with 1 other
Phase 4
5 of 34
1 open now
Registered
31st of 34
by date

Among the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, this one is the 8th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 4, and was the 31st registered.

Respiratory Distress Syndrome, Newborn

123 studies on the registry are indexed under Respiratory Distress Syndrome, Newborn; 24 are open to participants now.

Browse Respiratory Distress Syndrome, Newborn studies →

Open to participants now

5 of the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Respiratory Distress Syndrome, Newborn studies recruiting now, 2 (17%) set no upper age limit and 10 (83%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: Up to 15 Minutes · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?

Read the detailed description

RESEARCH DESIGN Multicenter, randomized, controlled trial.

Northshore Evanston Hospital will be the primary site. It is hoped that Northwest Community, University of Chicago, Edwards Hospital, Advocate Park Ridge, Advocate Oak Lawn and Advocate Illinois Masonic will also join the study.

RECRUITMENT Entry criteria Inborn preterm infants 22 0/7-29 6/7 weeks' gestation, with be randomized to prophylactic Minimally Invasive Surfactant Therapy (MIST) in the delivery room compared to rescue MIST if fraction of inspired oxygen (FiO2) ≥0.30 at less than 48 hours of age. Babies in both groups will be managed on nasal continuous positive airway pressure (NCPAP) pressures of 5-8 cm water.

Exclusion criteria Infants will be excluded if there is a congenital anomaly or an alternative cause for respiratory distress.

Babies who require emergent intubation in the delivery room will not be enrolled in the interventions.

Parental Consent will be obtained prior to birth. Once delivery is imminent infant will be randomized to immediate versus rescue surfactant administration via MIST. Randomization will be in blocks of 6 and using cards with created by a web based randomizer.

Infants who require emergent intubation in the delivery room will not be enrolled in the interventions but their clinical outcomes will be assessed the same as the babies who receive the intervention.

There will be three gestational age strata (22-23 weeks, 24-26 weeks and 27-29 weeks). Twins and higher order multiples will be randomized independently. Babies in the lowest gestational age strata will not be enrolled at a center until 5 babies at that center have been enrolled in either of the other groups.

INTERVENTION Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16 Gauge Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes). The infants will be stabilized and placed on NCPAP or High flow Nasal Cannula (HFNC).

Briefly the MIST procedure is as follows: the angiocath is inserted to an appropriate depth under direct laryngoscopy, the laryngoscope is removed, a carbon dioxide (CO2) detector is placed on the end of the catheter with a endotracheal tube adaptor. If the color changes then adaptor and detector are removed and the surfactant is instilled over about 1 minute and the catheter is removed. The infant is maintained on NCPAP/HFNC during the procedure.

Infants of both groups will be supported via HFNC or NCPAP in the delivery room and then transitioned to NCPAP in the neonatal intensive care unit (NICU).

The control group will be given surfactant via MIST if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.

A second dose of poractant alfa (Curosurf), at a dosage of 100mg/kg, will be administered via MIST to both groups if their fiO2 reaches the threshold of 30% between 6 and 48 hours after the first dose.

No further surfactant should be given in the first 7 days unless the infant reaches the intubation criteria.

POST-INTERVENTION MANAGEMENT Other than the requirement to adhere to intubation criteria in the first week, and in some cases perform a room air trial at 36 weeks corrected gestation, management will be at the discretion of the clinical team.

Titration of CPAP pressure is encouraged, with a permitted maximum of 8 cm H2O. Use of nasal intermittent positive-pressure ventilation (NIPPV) is allowable for apnea, but discouraged for Respiratory Distress Syndrome (RDS) and should only be after at least one dose of surfactant has been given.

Early caffeine therapy is expected.

Criteria for intubation:

Enrolled infants on CPAP will be intubated if:

  • FiO2 ≥0.45 for 15 minutes, or if there is unremitting apnea (> 6 episodes/hour requiring intervention or in the opinion of the treating physician) or persistent respiratory acidosis (pH\<7.25 and partial pressure of carbon dioxide (pCO2) >60) on blood gasses at least 30 minutes apart or metabolic acidosis refractory to treatment.
  • Need for an anesthetic or an intervention requiring intubation

These criteria apply during the first week of life, and to the first episode of intubation only. If the infant is intubated it is expected that another dose of surfactant will be administered.

OUTCOMES Primary outcome: Intubation in the first 7 days of age.

Secondary outcomes:

  • Respiratory Incidence of composite outcome of death or physiological bronchopulmonary dysplasia (BPD). Durations of mechanical respiratory support, CPAP, high flow nasal cannula, (HFNC), oxygen therapy. Pneumothorax or pulmonary hemorrhage.
  • Non respiratory neonatal morbidities intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotizing enterocolitis, and patent ductus arteriosus. Corrected age at discharge, length of hospital stay (a proxy for cost). Neonatal follow up data.

The above data will be collected until discharge. Babies born between 22 and 29 weeks are routinely followed by our developmental follow up clinic. The information from the 2-year developmental clinic visit will be recorded by the study.

SAMPLE SIZE 200, 50 being from NorthShore. Between 2018 and 2022 65% of the babies in this gestational age had an endotracheal tube inserted at Evanston Hospital, and were ventilated. Detection of a reduction of 25% (from 65% to 40%) with a 90% power and α = 0.05 (two-sided) would require 82 subjects per arm. It is anticipated that patient recruitment should take 2 years.

03

Conditions studied

  • Respiratory Distress Syndrome, Newborn
  • Premature Birth

Keywords

  • Respiratory Distress Syndrome
  • surfactant
  • Minimally invasive Surfactant Therapy
04

Who can participate

Ages eligible
Up to 15 Minutes
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age \<30 weeks
  • Antenatal consent from Parent

Exclusion criteria

Exclusion Criteria:

  • Congenital anomalies
  • Alternate cause of respiratory distress
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Prophylactic Surfactant via Minimally Invasive Technique

    Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes).

    Drug: Poractant Alfa

  • Active comparator
    Rescue Surfactant via Minimally Invasive Technique

    The control group will be given surfactant will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.

    Drug: Poractant Alfa

Interventions

  • Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter

    Also known as: Minimally Invasive Surfactant Therapy

06

What researchers measure

Primary outcomes

  1. Endotracheal Intubation

    Oxygen requirement \> 45% requiring endotracheal intubation

    Time frame: 7 days

Secondary outcomes

  1. Bronchopulmonary dysplasia

    Oxygen requirement to 36 weeks corrected age

    Time frame: 36 weeks corrected gestational age

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Dargaville PA, Kamlin COF, Orsini F, Wang X, De Paoli AG, Kanmaz Kutman HG, Cetinkaya M, Kornhauser-Cerar L, Derrick M, Ozkan H, Hulzebos CV, Schmolzer GM, Aiyappan A, Lemyre B, Kuo S, Rajadurai VS, O'Shea J, Biniwale M, Ramanathan R, Kushnir A, Bader D, Thomas MR, Chakraborty M, Buksh MJ, Bhatia R, Sullivan CL, Shinwell ES, Dyson A, Barker DP, Kugelman A, Donovan TJ, Tauscher MK, Murthy V, Ali SKM, Yossuck P, Clark HW, Soll RF, Carlin JB, Davis PG; OPTIMIST-A Trial Investigators. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA. 2021 Dec 28;326(24):2478-2487. doi: 10.1001/jama.2021.21892. PubMed 34902013 ↗
  • Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, Sinkin RA, Bartoletti A, Dweck HS, Horgan MJ, et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med. 1991 Mar 28;324(13):865-71. doi: 10.1056/NEJM199103283241301. PubMed 2000109 ↗
  • Kribs A, Hartel C, Kattner E, Vochem M, Kuster H, Moller J, Muller D, Segerer H, Wieg C, Gebauer C, Nikischin W, Wense Av, Herting E, Roth B, Gopel W. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Padiatr. 2010 Jan-Feb;222(1):13-7. doi: 10.1055/s-0029-1241867. Epub 2010 Jan 18. PubMed 20084586 ↗
  • Kattwinkel J, Bloom BT, Delmore P, Davis CL, Farrell E, Friss H, Jung AL, King K, Mueller D. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics. 1993 Jul;92(1):90-8. PubMed 8516091 ↗
  • SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network; Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Donovan EF, Newman NS, Ambalavanan N, Frantz ID 3rd, Buchter S, Sanchez PJ, Kennedy KA, Laroia N, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Bhandari V, Watterberg KL, Higgins RD. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010 May 27;362(21):1970-9. doi: 10.1056/NEJMoa0911783. Epub 2010 May 16. PubMed 20472939 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2023
First posted
Aug 23, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jul 31, 2027
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06007547
Lead sponsor
Endeavor Health
Collaborators
Chiesi USA, Inc.
Responsible party
Matthew Derrick (Attending Neonatologist, Endeavor Health) — Principal investigator
First posted
Aug 23, 2023
Start date
Jan 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Aug 7, 2025

Study contacts

Matthew Derrick, MBBS
Contact
mderrick@northshore.org
8475702920
Matthew Derrick, MBBS
principal investigator · Northshore Univ Healthsystem

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poractant alfa

Start the discussion